Neisseria Meningitidis Serogroup A Tetanus Toxoid Conjugate Vaccine
This vaccine provides active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroup A. It is a conjugate vaccine that links the bacterial capsular polysaccharide to a tetanus toxoid protein carrier to enhance immune response, particularly in younger age groups. The vaccine is primarily used in regions where serogroup A meningococcal disease is endemic or during outbreak situations.
A conjugate vaccine that protects against meningococcal serogroup A disease by training the immune system to recognize and fight the bacteria.
Key facts at a glance
- RxNorm
- 2360571
- Generic
- Neisseria Meningitidis Serogroup A Capsular Polysaccharide Tetanus Toxoid Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Menquadfi, Penbraya
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup A in individuals of appropriate age groups as determined by national immunization programs. Widely used in sub-Saharan African countries within the 'meningitis belt' where serogroup A outbreaks are common.
The vaccine contains purified capsular polysaccharide from N. meningitidis serogroup A, conjugated (chemically linked) to tetanus toxoid protein. This conjugation converts a T-cell independent antigen into a T-cell dependent antigen, producing stronger and longer-lasting immune responses, especially in children under 2 years of age who typically respond poorly to polysaccharide vaccines alone.
As with all vaccines, complete protection may not be guaranteed in all recipients. The vaccine does not protect against other serogroups of N. meningitidis (such as B, C, W, X, or Y). Side effects are generally mild and may include injection site reactions, fever, or headache. Contraindications include known hypersensitivity to any vaccine component.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 29, 2026. · Read our editorial policy